A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
Jay Talati, MD; Kevin Pierre, MD; Gia Serrano; Chase Labiste, MD; Jeffrey Vogel, MD; Hugh Davis, MD
A 52-year-old woman with a history of kidney and pancreas transplantation (17 years prior), end-stage renal disease on dialysis, type 1 diabetes mellitus, hypertension, and class 2 pulmonary hypertension...
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
The Consultant360 Multidisciplinary Roundtable on the September 2025 ACIP (Advisory Committee on Immunization Practices) updates brought together leading vaccine experts—including Drs Bonnie Maldonado, Art...
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
The November issue of Consultant brings together a diverse collection of case reports, from rare vascular emergencies to transplant-related complications and persistent hip pain following a fall. With each...
In this episode of Ask the Experts, dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares what's unique about the formulations of ZORYVE® (roflumilast). Mr. DiRuggiero discusses how...
Jay Talati, MD; Kevin Pierre, MD; Gia Serrano; Chase Labiste, MD; Jeffrey Vogel, MD; Hugh Davis, MD
A 52-year-old woman with a history of kidney and pancreas transplantation (17 years prior), end-stage renal disease on dialysis, type 1 diabetes mellitus, hypertension, and class 2 pulmonary hypertension...
A 35-year-old woman with systemic lupus erythematosus, antiphospholipid syndrome, chronic urticaria, asthma, Hashimoto thyroiditis, and recurring seizures presented to dermatology with a 3-month rash.
...
Advanced or recurrent endometrial cancer has long meant limited paths forward. But that may be changing. In this short video, two experts share compelling phase 3 data on a treatment option and what it could mean for real-world care.
